Filtered By:
Condition: Bleeding
Education: Academia
This page shows you your search results in order of date. This is page number 7.
Order by Relevance | Date
Total 422 results found since Jan 2013.
Impact of Denture Use on Ischemic and Bleeding Outcomes of Patients with Acute Myocardial Infarction
Conclusions More than one-third of the patients with acute MI wore dentures. Our findings suggest that denture use is significantly associated with an increased risk of ischemic events but not bleeding outcomes after acute MI.PMID:36130888 | DOI:10.2169/internalmedicine.0306-22
Source: Internal Medicine - September 21, 2022 Category: Internal Medicine Authors: Daichi Yamashita Yuichi Saito Takanori Sato Tadahiro Matsumoto Sakuramaru Suzuki Kan Saito Shinichi Wakabayashi Hideki Kitahara Koichi Sano Yoshio Kobayashi Source Type: research
Body Mass Index and Major Adverse Events During Chronic Antiplatelet Monotherapy After Percutaneous Coronary Intervention With Drug-Eluting Stents - Results From the HOST-EXAM Trial
CONCLUSIONS: Lower BMI is associated with a higher risk of primary composite outcomes, which is primarily related to the events of all-cause death or major bleeding during chronic maintenance antiplatelet monotherapy after PCI with DES.PMID:36123011 | DOI:10.1253/circj.CJ-22-0344
Source: Circulation Journal - September 19, 2022 Category: Cardiology Authors: Ki-Bum Won Eun-Seok Shin Jeehoon Kang Han-Mo Yang Kyung Woo Park Kyoo-Rok Han Keon-Woong Moon Seok Kyu Oh Ung Kim Moo-Yong Rhee Doo-Il Kim Song-Yi Kim Sung-Yun Lee Jung-Kyu Han Bon-Kwon Koo Hyo-Soo Kim Source Type: research
A Multicenter, Phase 2, Randomized, Placebo-Controlled, Double-Blind, Parallel-Group, Dose-Finding Trial of the Oral Factor XIa Inhibitor Asundexian to Prevent Adverse Cardiovascular Outcomes Following Acute Myocardial Infarction
CONCLUSIONS: In patients with recent acute MI, 3 doses of asundexian, when added to aspirin plus a P2Y12 inhibitor, resulted in dose-dependent, near-complete inhibition of FXIa activity without a significant increase in bleeding and a low rate of ischemic events. These data support the investigation of asundexian at a dose of 50 mg daily in an adequately powered clinical trial of patients following acute MI.PMID:36030390 | DOI:10.1161/CIRCULATIONAHA.122.061612
Source: Circulation - August 28, 2022 Category: Cardiology Authors: Sunil V Rao Bodo Kirsch Deepak L Bhatt Andrzej Budaj Rosa Coppolecchia John Eikelboom Stefan K James W Schuyler Jones Bela Merkely Lars Keller Renicus S Hermanides Gianluca Campo Jos é Luis Ferreiro Taro Shibasaki Hardi Mundl John H Alexander Source Type: research
Perioperative Antiplatelet Bridging With Cangrelor: A Cohort Study and Narrative Review
CONCLUSION AND RELEVANCE: This study suggests that cangrelor bridging may be a reasonable alternative to holding oral P2Y12 inhibitors in patients requiring interruption of antiplatelet therapy for an urgent surgery/invasive procedure.PMID:36004393 | DOI:10.1177/10600280221120310
Source: The Annals of Pharmacotherapy - August 25, 2022 Category: Drugs & Pharmacology Authors: Alok Salgia Chelsea K Krueger Michael A Gillette Source Type: research
Ticagrelor with and without aspirin in patients with a prior coronary artery bypass graft undergoing percutaneous coronary intervention: the TWILIGHT-CABG study
CONCLUSIONS: In high-risk patients with prior CABG, ticagrelor monotherapy reduced bleeding without compromising ischaemic outcomes compared with ticagrelor plus aspirin.PMID:35979636 | DOI:10.4244/EIJ-D-22-00319
Source: EuroIntervention - August 18, 2022 Category: Cardiovascular & Thoracic Surgery Authors: Gennaro Sardella Frans J Beerkens George Dangas Davide Cao Usman Baber Samantha Sartori David J Cohen Carlo Briguori Robert Gil Johny Nicolas Zhongjie Zhang Dariusz Dudek Vijay Kunadian Ran Kornowski Giora Weisz Bimmer Claessen Steven O Marx Javier Escane Source Type: research
Ticagrelor or prasugrel in patients with acute coronary syndrome with off-hour versus on-hour presentation: a subgroup analysis of the ISAR-REACT 5 trial
ConclusionsIn patients with ACS planned to undergo an invasive treatment strategy, time of presentation (off-hours vs. on-hours) does not interact significantly with the relative efficacy and safety of ticagrelor vs. prasugrel.Clinical trial registration.NCT01944800.Graphical abstract
Source: Clinical Research in Cardiology - July 5, 2022 Category: Cardiology Source Type: research
Antithrombotic strategy variability in atrial fibrillation and obstructive coronary disease revascularised with percutaneous coronary intervention: primary results from the AVIATOR 2 international registry
CONCLUSIONS: The AVIATOR 2 study is the first digital health study examining physician-patient perspectives on ATT choices after AF-PCI. TT was the most common strategy without differences in 1-year outcomes in ATT strategy. Physicians rated safety first when prescribing ATT; patients feared stroke over bleeding.CLINICALTRIALS: gov: NCT02362659.PMID:35656720 | DOI:10.4244/EIJ-D-21-01044
Source: EuroIntervention - June 3, 2022 Category: Cardiovascular & Thoracic Surgery Authors: Jaya Chandrasekhar Usman Baber Samantha Sartori Ridhima Goel Johny Nicolas Birgit Vogel Clayton Snyder Annapoorna Kini Carlo Briguori Bernhard Witzenbichler Ioannis Iakovou Gennaro Sardella Kevin Marzo Anthony DeFranco Thomas Stuckey Alaide Chieffo Antoni Source Type: research
